Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus.

Emma MaterneHyon K ChoiBaijun ZhouKaren H Costenbader Yuqing Zhang April M Jorge

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2023)

Belimumab was associated with lower risks of serious infection than oral immunosuppressants. This finding should inform risk/benefit considerations for SLE treatment. This article is protected by copyright. All rights reserved.

Keyphrases

systemic lupus erythematosus
disease activity
human health
rheumatoid arthritis
risk assessment
combination therapy